Improving Clinical Decision Making with Engaging CME, Tools, & Resources
GLP-1 Use and AMD Risk
Barton Lynn Blackorby, MD
Katharine Talcott, MD
Hong-Uyen Hua, MD
Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
Identifying Central and Branch Retinal Vein Occlusion
Jessica Randolph, MD
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Ashkan Abbey, MD
Retinal Vein Occlusion: The Case for Prompt Treatment
Outcomes for PDR Patients LTFU for at Least 1 Year
Kyle Davis Kovacs, MD
Matt Starr, MD
Nita Valikodath, MD, MS
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Ryan Quigley
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
David Chin Yee, MD, FASRS
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Maria H. Berrocal, MD
Lejla Vajzovic, MD, FASRS
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Deepak Sambhara, MD
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Danny Mammo, MD
Diagnosis Delays in Stargardt Disease
Alexis Warren, MD
Jesse Sengillo, MD
Sruthi Arepalli, MD
Redefining The Cash-Pay Model in Modern Optometric Practice
Jason E. Compton, OD, FAAO
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Jennifer Caudle, DO, FACOFP
Michael Javaheri, MD, MSc, FASRS
Loading...
We're glad to see you're enjoying Eye Health Academy… but how about a more personalized experience?
Press cancel to remain on Eye Health Academy. Press the link below or the continue button to keep going.